论文部分内容阅读
目的:评价格列齐特缓释片联合阿卡波糖治疗2型糖尿病的有效性及安全性。方法:65例2型糖尿病患者根据血糖水平分为3组,分别给予格列齐特缓释片30mg、60mg、120mg,同时联合阿卡波糖片150mg治疗,观察各组血糖、糖化血红蛋白(HbAlc)水平。结果:联合治疗后,全组HbAlc从(8.8±0.75)%下降到(6.83±0.75)%,空腹血糖(FPG)从(9.7±1.86)mmol·L~(-1)下降到(6.56±0.40)mmol·L~(-1),餐后血糖(PPG)从(15.1±2.35)mmol·L~(-1)下降到(8.87±2.1)mmol·L~(-1)。治疗前后比较,差异有统计学意义(P<0.01)。且各剂量级患者治疗后HbAlc、FPG、PPG均较治疗前明显下降(P<0.01)。试验期间发生低血糖事件15次,与药物剂量无关。结论:格列齐特缓释片与阿卡波糖联合治疗可有效的降低2型糖尿病患者的HbAlc、FPG、PPG水平,实现HbAlc达标。
Objective: To evaluate the efficacy and safety of gliclazide extended release tablets combined with acarbose in the treatment of type 2 diabetes mellitus. Methods: Sixty-five patients with type 2 diabetes were divided into 3 groups according to their blood glucose levels. The patients were given gliclazide 30mg, 60mg and 120mg respectively, and combined with acarbose 150mg. The levels of blood glucose, glycosylated hemoglobin (HbA1c )Level. Results: Compared with the control group, the HbA1c decreased from (8.8 ± 0.75)% to (6.83 ± 0.75)% and the fasting blood glucose (FPG) decreased from (9.7 ± 1.86) mmol·L -1 to (6.56 ± 0.40) ) mmol·L -1 and postprandial plasma glucose (PPG) decreased from (15.1 ± 2.35) mmol·L -1 to (8.87 ± 2.1) mmol·L -1. Before and after treatment, the difference was statistically significant (P <0.01). HbA1c, FPG and PPG in each dose group were significantly lower than those before treatment (P <0.01). Hypoglycemic events occurred 15 times during the trial, independent of drug dose. Conclusion: The combination of gliclazide and acarbose can effectively reduce the levels of HbAlc, FPG and PPG in type 2 diabetic patients and achieve the goal of HbAlc.